Findings from a pooled analysis of two phase III trials, COMBI-d and COMBI-v, centered on outcomes with first-line dabrafenib plus trametinib vs either agent alone.
Lauren M. Dembeck
The results of the phase II trial examining combination immunotherapy were presented during the ASCO 2019 meeting.
The investigators looked at whether whole-brain radiotherapy improved outcomes in patients with melanoma brain metastasis.
Data from the largest randomized neoadjuvant trial in resectable stage IIIB–IVM1a melanoma to date were presented at ASCO 2019.
A phase III study comparing the efficacy and safety of nivolumab plus an experimental interleukin-2–based drug vs nivolumab alone in patients with metastatic melanoma is now enrolling patients.
The updated survival results from the COLUMBUS trial represent a promising new treatment option for patients with BRAF V600–mutant melanoma.
COMBI-i tested the anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF V600–mutant melanoma.
A large international study looked at whether pregnancy is safe after breast cancer for women who have a BRCA mutation.
Investigators are now enrolling for a phase III trial testing the experimental immunotherapy tilsotolimod plus ipilimumab in patients with advanced melanoma who have progressed on anti–PD-1 therapy.
Investigators are now enrolling patients for a phase III trial, KEYNOTE-716, to assess the efficacy and safety of adjuvant pembrolizumab in adult and pediatric patients with surgically resected high-risk stage II melanoma.